Epidemiological aspects of hadron therapy: A prospective nationwide study of the Austrian project MedAustron and the Austrian Society of Radiooncology (OEGRO)

详细信息    查看全文

• 作者：Mayer Ramona ; Mock Ulrike ; Jä ; ger Robert ; Pö ; tter Richard ; Vutuc Christian ; Eiter Helmut ; Krugmann Kristine ; Hammer Josef ; Hirn Brigitte ; Hawliczek Robert ; Knocke-Abulesz Tomas-Henrik ; Lukas Peter ; Nechville Elisabeth ; Pakisch Brigitte ; Papauschek Michael ; Raunik Wolfgang ; Rhomberg Walter ; S
• 关键词：MedAustron ; Hadron therapy ; Epidemiology ; Prospective survey ; Proton Therapy ; Carbon-ion Therapy
• 刊名：Radiotherapy and Oncology
• 出版年：2004
• 出版时间：December 2004
• 年：2004
• 卷：73
• 期：Supplement 2
• 页码：S24-S28
• 全文大小：414 K

文摘

Summary

Background:

The planned MedAustron hadron therapy facility is designed to compare proton and carbon ion beam therapy under the same technical conditions. For the calculation of the number of potential patients for hadron therapy so far, only epidemiological estimations on cancer incidence are available without inclusion of the percentage of patients routinely referred to conventional radiotherapy

Materials and Methods:

Nationwide prospective survey to collect disease and treatment related data on patients receiving conventional radiotherapy at all 12 treatment facilities. Epidemiological cancer incidence (Statistic Austria 1999) were correlated with the number of patients receiving conventional radiotherapy. Based on published clinical and experimental results on proton and carbon ion therapy, a calculation of patient's subgroups suitable for hadron therapy was performed at five European University hospitals involved in the HICAT, CNAO, ETOILE and MEDAustron project. Using the mean values of the University specific percentages per tumour site, the number of potential patients was estimated.

Results:

In Austria, a total of 3783 patients started radiotherapy during the study period of 3 months resulting in an approximated number of 15132 patients per year. The number of potential patients was estimated to 2044 per year, representing 5.6 % of all newly diagnosed cancer patients and 13.5 % of all irradiated cancer patients.

Conclusion:

There is a clear place for a hadron therapy facility in Austria, based on pattern of care in radiotherapy, cancer incidence and indications.